MONOPRIL-HCT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Monopril-hct, and when can generic versions of Monopril-hct launch?
Monopril-hct is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in MONOPRIL-HCT is fosinopril sodium; hydrochlorothiazide. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fosinopril sodium; hydrochlorothiazide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Monopril-hct
A generic version of MONOPRIL-HCT was approved as fosinopril sodium; hydrochlorothiazide by SANDOZ on September 28th, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MONOPRIL-HCT?
- What are the global sales for MONOPRIL-HCT?
- What is Average Wholesale Price for MONOPRIL-HCT?
Summary for MONOPRIL-HCT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 5 |
| DailyMed Link: | MONOPRIL-HCT at DailyMed |
Recent Clinical Trials for MONOPRIL-HCT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Nebraska | Phase 4 |
| Ranbaxy Laboratories Limited | N/A |
US Patents and Regulatory Information for MONOPRIL-HCT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | MONOPRIL-HCT | fosinopril sodium; hydrochlorothiazide | TABLET;ORAL | 020286-002 | Nov 30, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | MONOPRIL-HCT | fosinopril sodium; hydrochlorothiazide | TABLET;ORAL | 020286-001 | Nov 30, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MONOPRIL-HCT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | MONOPRIL-HCT | fosinopril sodium; hydrochlorothiazide | TABLET;ORAL | 020286-002 | Nov 30, 1994 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol Myers Squibb | MONOPRIL-HCT | fosinopril sodium; hydrochlorothiazide | TABLET;ORAL | 020286-001 | Nov 30, 1994 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol Myers Squibb | MONOPRIL-HCT | fosinopril sodium; hydrochlorothiazide | TABLET;ORAL | 020286-001 | Nov 30, 1994 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MONOPRIL-HCT
See the table below for patents covering MONOPRIL-HCT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 0053902 | PHOSPHINYLALKANOYL SUBSTITUTED PROLINES | ⤷ Sign Up |
| European Patent Office | 0408273 | Formulations des comprimés contenant du fosinopril. (Fosinopril tablet formulations.) | ⤷ Sign Up |
| Germany | 3169744 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MONOPRIL-HCT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0053902 | SPC/GB96/024 | United Kingdom | ⤷ Sign Up | SPC/GB96/024:, EXPIRES: 20061126 |
| 0053902 | 96C0036 | Belgium | ⤷ Sign Up | PRODUCT NAME: FAMCICLOVIR; NAT. REGISTRATION NO/DATE: NL 21325 19960708; FIRST REGISTRATION: GB - 10592/0035 19931210 |
| 0053902 | SPC/GB93/028 | United Kingdom | ⤷ Sign Up | SPC/GB93/028, EXPIRES: 20050702 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
